FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / publication-rights-correspondence.docx
publication-rights-correspondence.docx · 1018-00004

Parties

HARKNESS LLP
Callahan LLP
Penterra Pharmaceuticals Corp

Dates

May 22, 2023
April 28, 2023
May 19, 2023
May 30, 2023
August 14, 2023
June 9, 2023

Amounts

$80,000,000
$1,500,000

Obligations

The silence of Veridian's proposed language on this point is, in our view, a significant gap that must be addressed regardless of the outcome of the review-period discussion
The sixty-day period shall commence on the date of Penterra's receipt of the complete Proposed Publication
The investigator shall consider such comments in good faith
If Penterra does not provide any written comments, requests for redaction, or notice of patentable subject matter to the investigator within the sixty (60)-day review period, the investigator shall be free to submit the Proposed Publication for publication or public presentation without further delay or restriction
Penterra's failure to respond within the sixty-day period shall be deemed consent to publication of the Proposed Publication as submitted
If Penterra does not exercise the Patent Delay option within the sixty-day window, the investigator shall be free to proceed with publication at the conclusion of the sixty-day review period